EICHORCondition: Breast Cancer · Sponsor: Eisai Inc.
The primary purpose of the Dose Optimization (Part 1) of this study is to assess the safety and tolerability of BB-1701 and to determine the recommended dose (RD) of BB-1701 for Dose Expansion (Part 2). The primary purpose of Dose Expansion (Part 2) is to assess the antitumor activity of BB-1701 at RD in the selected population(s) of breast cancer (BC).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Cancer and Blood Specialty Clinic | Los Alamitos, California, United States | — |
| UCLA Center for East-West Medicine | Los Angeles, California, United States | — |
| UCSF | San Francisco, California, United States | — |
| Yale New Haven Hospital | New Haven, Connecticut, United States | — |
| AdventHealth Cancer Institute - Orlando | Orlando, Florida, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| Fort Wayne Medical Oncology & Hematology | Fort Wayne, Indiana, United States | — |
| Community Cancer Center South | Indianapolis, Indiana, United States | — |
| Mission Blood and Cancer | Des Moines, Iowa, United States | — |
| University of Michigan Hospital | Ann Arbor, Michigan, United States | — |
| Washington University in St. Louis School of Medicine | St Louis, Missouri, United States | — |
| NHO Revive Research Institute LLC | Lincoln, Nebraska, United States | — |
+ 37 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06188559